Effect of Remote Ischemic Preconditioning on Collaterals of Atherosclerosis Stroke (NCT06170944) | Clinical Trial Compass
RecruitingNot Applicable
Effect of Remote Ischemic Preconditioning on Collaterals of Atherosclerosis Stroke
China300 participantsStarted 2024-06-01
Plain-language summary
The goal of this clinical trial is to explore the influence of chronic RIC on collateral status evaluated by DSA in ischemic stroke patients with LAA etiology.
Who can participate
Age range
40 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* 1\. Age over 40 years old;
* 2\. Diagnosed with ischemic stroke (including TIA and cerebral infarction), with onset time of more than 1 month;
* 3\. Culprit arteries are the large arteries of the anterior circulation with atherosclerotic stenosis (≥50%) or occlusion;
* 4\. ASITN/SIR collateral circulation of 0-3 based on DSA evaluation;
* 5\. First onset or prior onset with no significant sequelae (mRS ≤ 2);
* 6\. Those who are not expected to undergo angioplasty within 12 months (judged by the doctor or decided by patients and/or their representatives);
* 7\. The availability of informed consent.
Exclusion Criteria:
* 1\) Patients with severe infection or serious diseases such as liver, kidney, hematopoietic system, endocrine system, etc.;
* 2\) Patients with a history of stroke and severe sequelae (mRS≥3);
* 3\) arterial stenosis due to aortic dissection, moyamoya disease; Any known vasculitic disease; herpes zoster, varicella-zoster or other viral infections with vascular lesions; neurosyphilis; other intracranial infections; any intracranial artery stenosis associated with hypercytosis of cerebrospinal fluid; radiation-induced vascular lesions; myofiber dysplasia; sickle cell disease; neurofibromas; benign vascular lesions of the central nervous system; postpartum vascular disease; stenosis of the intracranial arteries due to vasospasm or thrombosm;
* 4\) Uncontrolled severe hypertension (systolic pressure≥180mmHg or diastolic pressure≥110 mmHg af…
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
The proportion of collateral status improvement.
Timeframe: 12 months
Trial details
NCT IDNCT06170944
SponsorGeneral Hospital of Shenyang Military Region